Ventripoint Diagnostics Ltd.
Great article on Ventripoint Diagnostics Ltd. (VPT.V) over at The Deep Dive.
Month: June 2021
Tocvan Announces Agreement with Millrock for El Picacho Project Sonora, Mexico
Adds to Portfolio with Project in Caborca Orogenic Gold Belt
Tocvan Ventures Corp. (CSE:TOC) (CNSX:TOC.CN) (“Tocvan” or the “Corporation”) is pleased to announce it has signed a Letter of Commitment with Millrock Resources Inc. to acquire the Option Agreement (“Agreement”) for the El Picacho Gold Project (the “Project”) within the Caborca Orogenic Gold Belt in Sonora, Mexico. The Project is located 140 kilometers north of Hermosillo in Sonora, Mexico and is fully accessible by road. Extensive surface exploration has been conducted historically defining five (5) gold targets on the project. Tocvan believes these targets will be ready for drill testing with surface confirmation via trenching. A permit is currently active to allow for trenching and drilling on the Project. A site-visit has been completed by Tocvan to confirm target areas and project accessibility. The Agreement is subject to an additional 60-day due-diligence period effective June 7, 2021.
GR Silver Mining Reports Drill Results Including a High-grade Au-rich Polymetallic Vein from the Plomosas Mine Area
GR Silver Mining Ltd. (TSXV: GRSL) (OTCQB: GRSLF) (FRANKFURT: GPE) (“GR Silver Mining” or the “Company”) – is pleased to report drill results in the northern portion of the Plomosas Mine Area. These results represent intersections of polymetallic (Ag-Au-Pb-Zn) hydrothermal breccia near the surface in unmined areas in the historic Plomosas Mine Area (Figure 1) at the Plomosas Silver Project (“Plomosas Project”) in Sinaloa, Mexico.
Ground Magnetic Survey Confirms and Expands Target Areas at Eloro Resources’ Iska Iska Silver-Tin Polymetallic Project, Bolivia
Eloro Resources Ltd. (TSX-V: ELO; OTCQX: ELRRF FSE: P2QM) (“Eloro”, or the “Company”) is pleased to report results from its recently completely magnetics survey on the Company’s Iska Iska silver-tin polymetallic project in Potosi Department, southern Bolivia. A total of 181.5 linekm of magnetic data were collected on 50m spaced north-south lines on all of the accessible parts of the property.
Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1
Dosing is complete in first of three human clinical studies hoped to validate Lexaria’s patented technology for hypertension relief – Study tested an advanced “DehydraTECH™ 2.0” CBD formulation – Second human clinical study, HYPER-H21-2, to commence immediately
Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to report that treatment and dosing in its human clinical study (HYPER-H21-1) have been completed ahead of schedule.
Gran Colombia Completes Arrangement with Gold X for the Creation of a New Mid-Tier Latin American Gold Producer
Gran Colombia Gold Corp. (TSX: GCM; OTCQX: TPRFF) (“Gran Colombia”) announced today the completion of its acquisition of all of the issued and outstanding common shares (the “Gold X Shares”) of Gold X Mining Corp. (TSXV: GLDX) (“Gold X”) not already owned by Gran Colombia by way of a statutory plan of arrangement (the “Arrangement”) under the Business Corporations Act (British Columbia). The Arrangement became effective at 12:01 a.m. (Pacific Time) on June 4, 2021 (the “Effective Time”). As a result of the Arrangement, Gold X became a direct, wholly-owned subsidiary of Gran Colombia and Gran Colombia gained control of the Toroparu Gold Project located in Guyana, South America.
Lexaria’s DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus
Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that remdesivir and ebastine processed with DehydraTECH were effective at inhibiting the COVID-19 SARS-CoV-2 virus using an in vitro screening assay in infected cells in Lexaria study VIRAL-C21-3.